30-Day Insulin Balance and Metabolic Health Program
Official title: 30 Day Insulin Balance Metabolic Health Optimization Protocol
Run by Efforia, Inc · NCT07478497 · Data updated 2026-11-12
This 30-day program will see if taking the Insulin Balance dietary supplement helps generally healthy adults maintain healthy insulin levels and reduce weight, fatigue, and sugar cravings.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Efforia, Inc Industry-sponsored |
| Locations | 1 site (New York, New York) |
| Status | Recruiting |
| Started | October 21, 2025 |
| Main results expected | October 21, 2026 |
| Study ends | October 21, 2026 |
| Registry record updated | March 17, 2026 |
| Trial ID | NCT07478497 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults age 18 and older who are generally healthy, can read English, give informed consent, and can follow daily supplement and questionnaire procedures are ideal candidates.
✕Probably not a fit
People with diagnosed insulin disorders, GI, sleep, or mental health disorders, pregnant or nursing individuals, those on medications, people with known allergies to the product, competitive athletes under specific regulations, and those sensitive to fatigue are excluded and unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This single-arm, 30-day Signal Phase program asks generally healthy adults to take the Insulin Balance Formula daily and serve as their own controls. Participants begin with one capsule to assess tolerance and progress to three capsules daily (ideally one before each meal) while completing body composition measures and questionnaires on sleep disturbance, carbohydrate cravings, and after-meal hunger and fatigue. The protocol is observational and designed to detect early signs of metabolic and weight-related benefit while collecting initial safety data. Findings will be used to inform whether larger, controlled trials are warranted.
Why it matters
Potential benefit: If successful, the supplement could help adults maintain healthier insulin levels and modestly improve weight, energy, and sugar cravings.
How similar studies have gone: Previous small trials of dietary supplements targeting insulin and metabolic symptoms have produced mixed, limited results, and well-controlled evidence is lacking.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults 18+ who are generally healthy * Ability to read and comprehend English * Ability to willfully consent and follow study procedures and tasks Exclusion Criteria: * Individuals with Known Allergies * Pregnant or Nursing Individuals * Individuals with Insulin Disorders * Individuals with GI Disorders * Individuals with Mental Health Conditions * Individuals with Sleep Disorders * Individuals on Medication * Athletes under Specific Regulations * Individuals Sensitive to Fatigue
Where it's running
-
Efforia
New York, New York, United States Recruiting
Study contacts
- Study coordinator: Matthew Amsden
- Email: help@efforia.com
- Phone: (646) 679-2479
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Think-Find-Solve activities for insulin self-management in children with type 1 diabetes
A behavior-change activity book is tested with children aged 8–12 with type 1 diabetes and their parents to see if it improves daily insulin self-management.
-
A new insulin-sensitizing pill for adults with type 1 diabetes using closed‑loop insulin delivery
This 12-week test will see if the oral drug CIR-0602K helps adults with type 1 diabetes who use closed-loop insulin systems spend more time in their target glucose range and use less insulin.
-
Automated insulin therapy for young children with type 1 diabetes
This study tests if a new automated insulin delivery system can improve the quality of life and blood sugar control for young children with type 1 diabetes compared to traditional methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.